Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD1 | P21728 | 5/20 | 0.51 |
| ▸ | DRD2 | P14416 | 3/20 | 0.48 |
| ▸ | DRD4 | P21917 | 2/20 | 0.48 |
| ▸ | DRD5 | P21918 | 2/20 | 0.48 |
| ▸ | DRD3 | P35462 | 2/20 | 0.48 |
| ▸ | HTR2C | P28335 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | CA1 | P00915 | 6/20 | 0.44 |
| ▸ | CA2 | P00918 | 6/20 | 0.44 |
| ▸ | CA9 | Q16790 | 6/20 | 0.44 |
| ▸ | CA14 | Q9ULX7 | 6/20 | 0.44 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.43 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.43 |
| ▸ | CA7 | P43166 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19439323 | 0.92 | DRD1 (0.47) | DRD1DRD2DRD4DRD5DRD3 | |
| SCHEMBL8024197 | 0.83 | MAOA (0.60) | DRD1DRD2DRD4DRD5DRD3 | |
| SCHEMBL5514232 | 0.83 | DRD1 (0.53) | DRD1DRD2DRD4DRD5DRD3 | |
| SCHEMBL5512737 | 0.80 | CA1 (0.63) | DRD1CA1CA2CA9CA14 | |
| SCHEMBL5519137 | 0.78 | DRD1 (0.60) | DRD1DRD2DRD4DRD5DRD3 | |
| SCHEMBL5525385 | 0.78 | ESR1 (0.62) | DRD1DRD2DRD4DRD5DRD3 | |
| SCHEMBL5518169 | 0.78 | CA1 (0.51) | DRD1DRD2DRD4DRD5DRD3 | |
| SCHEMBL5515316 | 0.78 | CA1 (0.53) | DRD1DRD2DRD4DRD5DRD3 | |
| SCHEMBL6713488 | 0.77 | ESR1 (0.61) | DRD1CA1CA2CA9CA14 | |
| Hydrochloric Acid SCHEMBL3767343 | 0.77 | ESR1 (0.57) | DRD1CA1CA2CA9CA14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7256201-B2 | Selective estrogen receptor-β ligands | ASTRAZENECA AB (SE) | 2007-08-14 | — | — | US | disclosed |
| US-20050101584-A1 | Selective estrogen receptor-beta ligands | ASTRAZENECA AB (SE) | 2005-05-12 | — | — | US | disclosed |
| EP-1341765-A1 | THERAPEUTIC COMPOUNDS | AstraZeneca AB (SE) | 2003-09-10 | — | — | EP | disclosed |
| WO-2002046164-A1 | THERAPEUTIC COMPOUNDS | ASTRAZENECA AB (SE) | 2002-06-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050101584-A1 | Selective estrogen receptor-beta ligands | ESR2, ESRRA, ESRRB | DRD1 753/4885DRD2 535/4885DRD4 521/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.